Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.
AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of one of the most aggressive cancers – acute myeloid leukaemia (AML).
Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer.
